Hematologic Malignancies—Plasma Cell Dyscrasia

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
Click also The Video Journal of Hematological Oncology (VJHemOnc) Link at the bottom of the page to watch a summary of the most important studies presented at ASCO 2020 in multiple myeloma
 
 
Paul G. Richardson, Annette J. Vangsted, Karthik Ramasamy, et al.
 
The abstract concludes: 
TEAEs of CC-92480 were mainly related to myelosuppression in heavily pretreated, including triple-class-refractory, RRMM pts. Promising activity with 48% ORR at therapeutic doses was observed. The study is ongoing to further optimize dose and schedule, with combination studies underway and dose expansion cohorts planned. Clinical trial information: NCT03374085.
————————————————————————————————————————————————————————————————————————————
 
 
Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, et al. 
 
The abstract concludes: 
BOSTON is the first phase 3 study to evaluate the clinical benefit of SVd for relapsed/refractory MM. The study met the primary endpoint: once weekly SVd significantly improved PFS and ORR compared to twice weekly Vd. Rates of PN were significantly reduced with numerically fewer deaths on SVd vs Vd. Full dataset will be presented at the meeting. Clinical trial information: NCT03110562.
 
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
 
Ajay K. Nooka, Keith Stockerl-Goldstein, Hang Quach, et al.
 
The abstract concludes: 
In DREAMM-6, preliminary data demonstrate that the combination of belantamab mafodotin and BorDex has an acceptable safety profile, with no new safety signals identified. Funding: GlaxoSmithKline (207497). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa. Clinical trial information: NCT03544281.
 
————————————————————————————————————————————————————————————————————————————
 
 
Nikhil C. Munshi, Larry D. Anderson, Jr, Nina Shah, et al.
 
The abstract concludes: 
Ide-cel demonstrated deep, durable responses in heavily pretreated RRMM pts. Efficacy and safety reflected prior reports and support a favorable ide-cel clinical benefit-risk profile across the target dose range. Clinical trial information: NCT03361748.
————————————————————————————————————————————————————————————————————————————
 
 
Sham Mailankody, Andrzej J. Jakubowiak, Myo Htut, et al.
 
The abstract concludes: 
Orva-cel at 300, 450, and 600 × 106 CAR+ T cells demonstrated manageable safety (CRS grade ≥3: 2%; NE grade ≥3: 4%) and compelling efficacy in heavily pretreated pts with RRMM, with a 91% objective response rate (ORR) and 39% complete response (CR)/stringent CR (sCR) rate. Updated results will be presented, including minimal residual disease, durability of response, and recommended phase 2 dose. Clinical trial information: NCT03430011.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
 
Jesus G. Berdeja, Deepu Madduri, Saad Zafar Usmani, et al.
 
The abstract concludes: 
JNJ-4528 treatment led to responses in all pts. These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up. CRS was manageable in most pts, supporting outpatient dosing. Clinical trial information: NCT03548207.
————————————————————————————————————————————————————————————————————————————
 
 
Parameswaran Hari, Marcelo C. Pasquini, Edward Allen Stadtmauer, et al.
 
The abstract concludes: 
Long term outcomes are similar using ITT, but as treated analysis suggested a PFS benefit for tandem autoHCT, driven mainly by pts with high risk MM. Len discontinuation even at 38 mo was associated with inferior PFS. Clinical trial information: NCT02322320.
————————————————————————————————————————————————————————————————————————————
 
 
Saad Zafar Usmani, Sikander Ailawadhi, Rachael Sexton, et al.
 
The abstract concludes: 
In the first randomized HRMM study reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. However, the PFS and OS seen in both arms of the study exceeded the original statistical assumptions and support the role for PI/IMiD combination maintenance therapy for this patient population. The S1211 data will serve as an important benchmark for future HRMM clinical trials. Clinical trial information: NCT01668719.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
The Video Journal of Hematological Oncology (VJHemOnc): Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, USA, takes you through a selection of the most important studies presented at ASCO 2020 in multiple myeloma:

ASCO 2020 | Highlights in multiple myeloma at ASCO 2020

————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
 
Poster Session
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Hematologic Malignancies (Abstracts #LBA3, 8500, 8502)
Access Content Now